What happens when you take dabigatran with St. John's wort?
Dabigatran (Pradaxa) is a direct thrombin inhibitor used to prevent strokes in atrial fibrillation and to treat or prevent venous blood clots. It is given as a prodrug (dabigatran etexilate) and is heavily dependent on the P-glycoprotein (P-gp) transporter system for its absorption and disposition.
St. John's wort (Hypericum perforatum) is a popular herbal antidepressant. Its main active constituent, hyperforin, is one of the most potent natural inducers of both cytochrome P450 3A4 and P-glycoprotein. Within about two weeks of regular use, St. John's wort can roughly double P-gp expression in the intestine and liver.
For dabigatran, that means more of the drug is pumped back out of cells and excreted before it can exert its anticoagulant effect. Plasma concentrations drop, the thrombin-blocking activity is weakened, and the patient may end up effectively under-anticoagulated despite taking the prescribed dose.
Why is this important?
Dabigatran is prescribed for serious indications: stroke prevention in atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent clots. The cost of subtherapeutic levels is not a side effect like nausea, it is a stroke, a clot, or a death.
Unlike warfarin, dabigatran does not have a routine blood test (INR) that patients monitor at home. So if St. John's wort silently lowers dabigatran levels, the first sign of the interaction may be a thromboembolic event. This is why dabigatran's official prescribing information specifically lists St. John's wort among P-gp inducers that should be avoided.
The effect is also slow to reverse. Once St. John's wort is stopped, it takes roughly one to two weeks for P-gp expression to return to baseline, leaving a stretch of time when dosing needs to be carefully reassessed.
What should you do?
Do not combine St. John's wort with dabigatran. If you are starting dabigatran and currently take St. John's wort, tell your prescriber before your first dose so the supplement can be stopped and an alternative considered. If you are already on dabigatran and have been taking St. John's wort, contact your prescriber rather than simply stopping on your own, because abrupt withdrawal can also disrupt the balance.
If you take St. John's wort for low mood or mild depression, talk to your doctor about evidence-based alternatives that do not induce P-gp, such as SSRIs (with awareness of their own bleeding considerations), SNRIs, bupropion, or non-drug options like cognitive behavioral therapy and exercise. For sleep, melatonin or behavioral sleep strategies are safer choices.
While taking dabigatran, watch for signs of inadequate anticoagulation: sudden facial droop, arm weakness, slurred speech, sudden severe headache, chest pain, shortness of breath, or new leg swelling and pain. These can signal stroke, pulmonary embolism, or deep vein thrombosis, and all require emergency evaluation.
Which specific products are affected?
On the medication side, this applies to dabigatran etexilate (Pradaxa) at all doses (75 mg, 110 mg, 150 mg). The same induction concern applies to the other DOACs that depend on P-gp and/or CYP3A4: apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa, Lixiana).
On the supplement side, this covers St. John's wort capsules, tablets, tinctures, teas, and combination mood or stress products. Look for Hypericum perforatum, hypericin, or hyperforin on labels. Many sleep and anti-anxiety formulas hide St. John's wort in proprietary blends.
The bottom line
St. John's wort is one of the few herbal interactions that is genuinely and consistently dangerous. By inducing P-glycoprotein, it can quietly drop dabigatran levels below the threshold needed to prevent clots, with potentially catastrophic consequences. If you take dabigatran, do not take St. John's wort. If you currently take both, call your prescriber, not the internet, before changing anything.